RGS17

Across TCGA pan-cancer cohorts, RGS17 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RGS17 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher RGS17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RGS17 expression acts as an unfavorable survival marker, although some lineages such as BRCA show a favorable association.

ESCA, COAD, and BRCA are the cancer types where RGS17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.102	0.703	<.001	36	view →
COAD	OS	Median	All	0.450	0.808	.013	3	view →
BRCA	OS	Median	All	0.927	0.924	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RGS17–ESCA (OS)

Open the ESCA breakdown →